EM-115126
1 December 2022
-
47 Minutes
The role of the multidisciplinary team in the management of patients with AL amyloidosis
Amyloidosis~Multiple Myeloma~myelomaconnect
EM-93566
30 November 2022
-
59 Minutes
Challenges in CLL: how could the data from ASH 2022 impact your clinical practice?
challengesincll~CLL
EM-92737
17 November 2022
-
47 Minutes
Challenges in NHL: Optimising first-line treatment in MCL
challengesinnhl~NHL
EM-92751
16 November 2022
-
46 Minutes
What are the key drivers for selecting ideal RRMM patients for treatment with CAR T-cell therapy?
Multiple Myeloma~myelomaconnect~RRMM
EM-93624
15 November 2022
-
44 Minutes
A focus on standard risk patients with MM and the roadmap to cure
Multiple Myeloma~myelomaconnect~NDMM
EM-93617
9 November 2022
-
50 Minutes
INSIDER: Highlights from the 11th International Workshop on Waldenström’s Macroglobulinemia
challengesinnhl~NHL
EM-96531
8 November 2022
-
46 Minutes
Challenges in CLL: Continuous, time-limited, or MRD-guided therapy
challengesincll~CLL
EM-92734
25 October 2022
-
49 Minutes
What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?
Multiple Myeloma~myelomaconnect~RRMM
EM-93607
4 October 2022
-
46 Minutes
How do we ensure we choose the right treatment for the right patient?
Multiple Myeloma~myelomaconnect~NDMM
EM-93604